Q&As

Want to search for the relevant question and answer in your own language? Change the language in the dropdown menu above.

The UKs withdrawal from the EU

BPR

The manufacturing site of the active substance / biocidal product that my EU-based company is placing on the EU/EEA market is located in the United Kingdom (Great Britain). Do we need to be concerned about the end of the transition period?

The BPR does not set any specific requirement regarding the location of the manufacturing site(s) of active substances or biocidal products. Therefore, manufacturing can take place in so-called “third countries”, including the UK (Great Britain) even after the end of the transition period. You will not need to take any action to continue complying with the BPR. However, shipments to the EU/EEA/Switzerland of this active substance/biocidal product will be, as of the end of the transition period, importations, which has consequences from the viewpoint of other sectorial legislation (e.g. the PIC Regulation, customs).

In Northern Ireland, the BPR Regulation continues to apply after the end of the transition period. This means that shipments to the EU/EEA/Switzerland of active substances/biocidal products will not be treated as importations for the purposes of the BPR Regulation. Please refer to Q&As 1703-1710 for further details.

The manufacturing site of a treated article that my EU-based company is placing on the EU/EEA market is located in the United Kingdom (Great Britain). Do we need to be concerned?

The BPR does not set any specific requirement regarding the location of the manufacturing site(s) of treated articles, which can be manufactured in third countries. Treated articles manufactured in third countries can be placed on the EU/EEA/Switzerland market if they meet the conditions of the BPR, in particular Articles 58 and 94. However, shipments to the EU/EEA/Switzerland of this treated article will be, as of the end of the transition period, importations, which has consequences from the viewpoint of other sectorial legislation (e.g. customs).

In Northern Ireland, the BPR Regulation continues to apply after the transition period. This means that shipments to the EU/EEA/Switzerland of treated articles will not be treated as importations for the purposes of the BPR Regulation. Please refer to Q&As 1703-1710 for further details.

What will happen to treated articles that are manufactured outside the EU/EEA and first imported into the UK(Great Britain) before the end of the transition period, and made available on the EU/EEA market after that date?

Any treated article placed on the EU/EEA market is subject to the provisions of the BPR, in particular Articles 58 and 94. After the end of the transition period, shipments from the United Kingdom (Great Britain) to the EU of a treated article will be considered as an import and, consequently, placing on the market of such treated article. If the treated article was placed on the UK market before the end of the transition period, it is expected to be compliant with the BPR already, and there should be no specific consequences as regards to compliance with the BPR (i.e. active substance approved in the EU/EEA, proper labelling information etc.). 

In Northern Ireland, the BPR Regulation continues to apply after the transition period. This means that shipments of a treated article from Northern Ireland to the EU will not be considered as an import for the purposes of the BPR Regulation. Please refer to Q&As 1703-1710 for further details.

The UK was acting as the reference Member State (refMS) in procedures in sequence (mutual recognition of a biocidal product authorisation in accordance with Articles 33 and 34 of the BPR, applications for minor or major changes under Commission Implementing Regulation (EU) No 354/2013) and renewal of product authorisations under Commission Delegated Regulation (EU) No 492/2014) related to my company’s product and the process is not yet finalised. What effect does the UK withdrawal have on the pending process?

As of the withdrawal date, the United Kingdom can no longer act as a leading authority in processes at Union level and, therefore, it can no longer be a reference MS (refMS) in above indicated processes.

For those applications which were submitted before the UK withdrawal date, the services of the European Commission and ECHA are working in a coordinated manner with EU Members States, EEA countries and Switzerland in order to try to identify new refMSs. The MSs at CA level and the coordination group will explore the possibilities to identify new refMSs.

Where it will not be possible to reach an agreement on identifying a new refMS, the pending process will be terminated.

Thus, the applicants are invited to actively try to identify a new refMS for pending sequence cases by themselves.

If the application for an above mentioned process was submitted after the UK withdrawal date it should be rejected by the relevant cMS(s). The applicant will need to find a new refMS and submit a new application. 

After the end of the transitional period, will an EU Member State still be able to issue a national biocidal product authorisation on the basis of the mutual recognition of a UK authorisation granted before the UK withdrawal?

No. For mutual recognitions in sequence, a concerned Member State (cMS) may proceed to grant a national product authorisation in accordance with Article 33(3) of the BPR provided that the mutual recognition takes place of a national authorisation granted in a Member State and  the applicant has chosen a new (EU-27/EEA/Switzerland) Reference Member State (RefMS).

For mutual recognitions in parallel, see Q&A 1545.

My EU based company benefits from an authorisation issued by an EU Member State prior to the UK withdrawal date on the basis of the recognition of a UK authorisation. Will my authorisation be affected by the UK withdrawal?

No. There will not be any such effect. The authorisation granted by each EU Member State will remain valid in these EU Member States. However, the authorisation holder has to be established in the EU, EEA country, or Switzerland before the end of the transitional period.

If your company is based in Northern Ireland you do not need to take action.

In Northern Ireland, the BPR Regulation continues to apply after the transition period. Please refer to Q&As 1703-1710 for further details.

My company is currently considering to submit an application under the BPR for which the UK authorities could act as evaluating Competent Authority (eCA) or reference Member State (refMS). How should we proceed?

Since the withdrawal date, the United Kingdom can no longer act as an eCA/refMS. This also applies during the transition period.

My company needs to submit an application for renewal of an approval of our active substance for which the UK acted as the evaluating Competent Authority (eCA) during the first approval procedure. Can my company choose another competent authority as eCA?

Yes. After the withdrawal, the United Kingdom can no longer act as an eCA.

This also applies during the transition period. This implies that one of the EU Member States, EEA countries and Switzerland has to act as eCA. Article 13(3) of the BPR does not require that the eCA for the first approval shall be the eCA for the renewal, although it is usually recommended as a means to streamline the process. The mentioned provision requires that, when you submit your application for renewal, you shall indicate the name of the competent authority that you propose for evaluating your application for renewal and provide written confirmation that that competent authority agrees to do so.

To achieve a smooth process, the services of the European Commission have agreed with the EU Member States, EEA countries and Switzerland on the new evaluating competent authority from among the competent authorities of the EU Member States.

My company needs to apply for a change or renewal of a product authorisation granted in a mutual recognition procedure in which the UK acted as the reference Member State (refMS). Can my company choose another competent authority as refMS?

Since the withdrawal date, the United Kingdom can no longer act as a refMS. This also applies during the transition period. 

Both the Commission Implementing Regulation (EU) No 354/2013 and the Commission Delegated Regulation (EU) No 492/2014 allow the authorisation holder to choose another refMS for the change as well as the renewal procedure. You will, however, need to submit within the application a written confirmation that the new competent authority agrees to act as refMS.

An EU Member State has granted my EU/EEA-based company a biocidal product authorisation based on mutual recognition of a UK biocidal product authorisation. Will my company’s product authorisation be affected by the UK withdrawal?

No. Your company has rights stemming from the national product authorisation granted by the authorities of the concerned Member State. As any such decision authorising a biocidal product on a national market is a national one, the UK withdrawal from the EU will not affect the validity of your company’s product authorisation, even if your national authorisation is based on the mutual recognition of a UK authorisation. 

My EU/EEA-based company is listed under Article 95 of the BPR as a supplier of a listed active substance for which we had purchased a letter of access (LoA) from a UK(Great Britain)-based company. Will the end of the transition period affect my company’s listing under Article 95 of the BPR?

No. Data owners granting letters of access do not need to be EU/EEA-based.

CLP

When exporting to the UK(Great Britain), will my EU/EEA-based company still need to include in the labels of our products the pictograms and other label elements that the CLP Regulation prescribes?

The label elements that are based on the United Nations’ Global Harmonised System (GHS) will remain obligatory as the UK(Great Britain) will still implement the GHS. Thus, for example, the pictograms will be valid within the UK(Great Britain).

When our EU/EEA-based company exports to the UK(Great Britain), will the labels affixed to our products still need to be in the English language as required by the CLP Regulation?

After the end of the transition period, the legal language requirements will depend on the future UK legislation. In practice, it is safe to assume a need to continue labelling your product in the English language as the official language of the UK, based on the information and the format prescribed by the CLP Regulation.

Northern Ireland Protocol

What impact will the withdrawal of the United Kingdom from the European Union have on my EU-based company?

As a company based in the EU/EEA, the obligations flowing from the EU chemicals legislation will continue to apply to you. Your interactions with UK(Great Britain)-based business partners, however, will be impacted by the UK withdrawal, as the United Kingdom has become a “third country” from 1 January 2021. 

For biocidal products, specific arrangements are put in place potentially affecting your company, as the UK cannot anymore act as a leading authority during the transition period.  In the end, you may face new and different UK rules on the import and use of chemical substances. You may also need to adapt your interaction in supply chains involving your UK(GB)-based business partners. The Q&A sections on the BPR, CLP, PIC and REACH Regulations will provide you with more detailed guidance in that regard.

In Northern Ireland, REACH, CLP, BPR and PIC continue to apply after the transition period. Please refer to Q&A 1700 - 1711 for an overview.

PIC

My EU-based company buys a product from a company based in the UK(Great Britain) and it is subsequently shipped directly to my customer who is based in another non-EU country. Do we need to notify the export?
As the product you hold the contract for does not come from an EU country nor is in free circulation within the EU custom territory, it does not fall within the notion of “export” pursuant to Article 3.16 (a) or (b) of the PIC Regulation. Consequently, no export notification will be needed under the EU PIC Regulation.
 
However, please note that the following circumstances may lead to exceptions:
 
  • Any national legislation regulating exports in place in the UK;
  • If the exported chemical is listed in Annex III to the Rotterdam Convention (as well as being subject to the EU PIC Regulation).
In Northern Ireland, the PIC Regulation continues to apply after the end of the transition period. Therefore, if the company shipping the product to a third country (i.e. any other custom territory than those of the EU and UK(Great Britain) is located in the Northern Ireland, and your company is the holder of the contract, then the EU company should notify the export to your DNA.
My EU-based company imports chemicals subject to PIC from companies based in the UK(Great Britain). Will we have any additional obligations after the end of the transition period?

Yes, pursuant to Article 10(1) of the PIC Regulation, in the first quarter of the year following the import you should provide details on the import(s) to your Designated National Authority (DNA) by means of ePIC.

In Northern Ireland the PIC Regulation continues to apply after the transition period; therefore,  shipments from companies located in Northern Ireland to the EU and vice-versa are not subject to such reporting obligations under PIC.

My EU-based company needs to notify an export of a chemical subject to the PIC Regulation to the UK (Great Britain)that will take place after the end of the transition period. How should I proceed?

Pursuant to Article 8(2) of Regulation (EU) No 649/2012 on the export and import of hazardous chemicals, exporters are required to notify their exports 35 days before the expected date of export. To cover exports taking place in 2021 ePIC has been updated to enable EU-based exporters to notify the planned export to the United Kingdom (Great Britain) in advance of the end of the transition period. 

In Northern Ireland the PIC Regulation continues to apply after the transition period, so shipments from the EU to Northern Ireland and vice-versa are not subject to PIC obligations.

REACH

My EU/EEA-based company is purchasing a chemical substance from a UK(Great Britain)-based business partner which has registered the substance under REACH. Can we still rely on the substance having been legally and validly registered within the EU/EEA in accordance with the REACH Regulation after the end of the transition period?

You are able to rely on the registration of a UK(Great Britain)-based legal entity until the end of the transition period. Thereafter, your business partner will need to appoint an Only Representative established within the EU/EEA or relocate to the EU/EEA for the substance to remain legally registered with ECHA for the EU/EEA. In the absence of such an appointment or relocation by your UK(Great Britain)-based supplier, you will need to register the substance yourself as an EU/EEA importer.

For registered substances in stock at the end of transition period, please see Q&A 1543.

In Northern Ireland, REACH continues to apply after the transition period. This means, inter alia, that registrants can continue to be based in Northern Ireland. Please refer to Q&A 1700.

My EU/EEA-based company is a registrant in a joint submission for which a UK(Great Britain)-based company is the Lead Registrant, as well as owner of the data to which we have obtained a Letter of Access. What impact will the end of the transition period from the EU have on our registration?

After the end of the transition period, the registration by the UK(Great Britain)-based company will be considered non-existent. If the UK(Great Britain)-based Lead Registrant still wishes to continue placing their substance on the EU/EEA market, they must take action. If they are a manufacturer of the substance, they can appoint an Only Representative located in the EU/EEA to handle their registration and the lead registrant duties. Alternatively, the UK(Great Britain) based manufacturer can transfer their existing registration to the EU/EEA, keeping the manufacturing role, if this transfer is the result of a legal entity change, falling into one of the following scenarios:

(a) the UK(Great Britain) based manufacturer goes through an acquisition or relocation to the EU/EEA;

(b) an intra-group transfer of the whole operation / manufacturing activity to the EU/EEA. Following the legal entity change to the EU/EEA manufacture, the UK(Great Britain) legal entity must cease manufacturing until the end of the transition period.

However, if they are an importer, the only way they can still retain the lead registrant role is by moving their import activities into the EU/EEA and changing the registrant legal entity in REACH-IT to this new legal entity.

If the UK(Great Britain) company does not wish to remain on the EU/EEA market and thus does not take the necessary actions, the members of the joint submission must agree on a new lead. The lead role can be taken by any member of the joint submission.

Agreements among registrants should include a provision regulating the case that the appointed Lead Registrant can no longer exercise their function and foreseeing that the shared information is transferred to a new lead registration, as well as arrangements to ensure data and cost sharing can be continued in the future.

In Northern Ireland, REACH continues to apply after the transition period. This means, inter alia, that registrants, including Lead Registrants, can continue to be based in Northern Ireland. Please refer to Q&A1700 for further details.

My company is a downstream user located in the EU/EEA and relies on a REACH Authorisation granted to a UK (Great Britain) supplier (or a pending application for an Authorisation). Will our use be covered after the end of the transition period?
Your use of an Annex XIV substance will be covered by the REACH Authorisation (or the pending Authorisation application) until the end of the transition period. After the end of the transition period, the REACH Regulation will no longer apply to the UK(Great Britain), and the REACH Authorisations (and pending authorisation applications) will lose their legal effect as of that date.
 
Therefore, you will need to rely on a supplier with a valid Authorisation (or with a pending authorisation application) in the EU/EEA. If your supplier does not hold an authorisation nor has applied for an Authorisation, and you wish to continue to use the Annex XIV substance after the end of the transition period, you will need to apply for an Authorisation yourself. We recommend that you contact your supplier, to ask them about their intentions.
 
As for UK(Great Britain)-based Authorisation holders (or authorisation applicants), there are a number of situations in which they can transfer their  Authorisation (or pending authorisation application) to EU/EEA:
 
  1. UK(Great Britain)-based manufacturers and formulators can transfer their Authorisation or pending application for authorisation to an Only Representative based in the EU/EEA;
  2. UK(Great Britain)-based Only Representatives can transfer their Authorisation or pending application for authorisation to a new Only Representative based in EU/EEA, appointed by the non-EU manufacturer (also see Q&A 1250). Please note however that UK(Great Britain)-based importers cannot transfer their Authorisation to an Only Representative in the EU/EEA.
  3. Like any EU/EEA-based legal entity, UK(Great Britain)-based legal entities can currently transfer their Authorisation or pending application for authorisation where the transfer is the result of the change of legal entity referred to in Q&A 1239 (for instance, as the result of a merger, a split or an asset sale (sale of a production site or business)) and the person to whom it is transferred qualifies as manufacturer, importer or downstream user with regard to the substance(s) and the use(s) covered by the application for authorisation or the decision. A change of legal entity cannot extend the scope of the original application for authorisation or of the Authorisation, e.g. to cover different uses. (Please see Q&A 1239 and Q&A 1241 to 1249).
With regard to the timing of such transfers:
 
  • In case 1, the transfer can only take effect at the end of the transition period (for detailed advice, please see Q&A 1466).
  • In cases 2 and 3, the transfer must take place before the end of the transition period and be notified to ECHA (through the ‘Legal entity change’ functionality in REACH-IT) without undue delay. In fact, ECHA recommends to initiate the transfer at least two weeks before the end of the transition period, to allow for a timely update should ECHA identify any issue with the attached documentation. It should also be noted that after this transfer, the UK-based company cannot continue its manufacturing / importing / Only Representative activity, as long as the REACH Regulation applies to the UK(GB). If the UK(GB)-based company only intends to implement the transfer at the end of the transition, it can include a suspensive clause in the transfer agreement with the successor company stipulating that the transfer takes effect at the end of the transition period. In this case, after the legal entity change is initiated in REACH-IT, the successor legal entity should review the transfer, but not proceed to accept it before the end of the transition period. (Please see also the instructions in the 'How to transfer your UK REACH registrations prior to the UK withdrawal from the EU' guide).
The advice provided above applies to both Authorisations and pending applications.
 
In Northern Ireland, REACH continues to apply after the transition period. This means, inter alia, that authorisation holders can continue to be based in Northern Ireland. Please refer to Q&A 1700 for further details..
What will happen to substance evaluations based on the Community Rolling Action Plan (CoRAP) 2012-2014 and its updates that are assigned to the UK authorities and were still be pending at the time of the UK withdrawal?

ECHA, in collaboration with the European Commission and Member State competent authorities, have reviewed all pending substance evaluations for appointing another Member State authority to take over the respective evaluation. The UK withdrawal has also been taken into consideration in the CoRAP updates for the years 2018-2020 as well as 2019-2021, and will continue to do so for subsequent updates.

My EU/EEA-based company obtains its supplies of a chemical substance from a UK(Great Britain)-based importer into the EU/EEA. When the transition period ends, our supplier will become an actor based in a “third country”. If we continue our business relations with our UK(Great Britain)-based supplier, would our UK(Great Britain)-based supplier be entitled to appoint our company as its Only Representative in the EU/EEA and transfer its registration to us, or would we need to register as an importer ourselves?

The latter is the case. You would need to act as an importer of the substance into the EU/EEA and submit a new registration. Article 8 of the REACH Regulation only allows manufacturers, formulators of mixtures or producers of articles established outside the EU/EEA to appoint an Only Representative. This option will thus not be available to UK(Great Britain)-based companies that will have been importers into the EU/EEA until the end of transition period. Thus, it is not possible to transfer a registration of a UK(Great Britain) importer to a newly appointed Only Representative. Non-EU/EEA manufacturers of the substance may of course appoint an EU/EEA-based Only Representative of the substance. However, such an Only Representative would then need to submit a new registration for the substance.

In Northern Ireland, REACH continues to apply after the transition period. Therefore, supplies from Northern Ireland will be considered as transfers within EU internal market and not as imports. Please refer to Q&A 1700.

My EU/EEA-based company purchases a mixture from a UK(Great Britain)-based company. Under the REACH and CLP Regulations, what impact has the end of the transition period on these supplies?

After the end of the transition period, your supplier will no longer be subject to REACH and CLP obligations. Therefore, you will need to ask your UK(Great Britain)-based supplier- if they will appoint an Only Representative to cover the necessary REACH registrations for the component substances of the mixture. If not, you will need to submit the relevant registrations as an importer yourself to be legally on the EU/EEA internal market.

Under CLP, you will now be the importer and thus will have the obligation to ensure that the imported mixture is correctly classified, labelled and packaged. You may also have the notification obligation to the Classification and Labelling Inventory.

In Northern Ireland, REACH and CLP continue to apply after the transition period. This means, inter alia, that REACH registrants can continue to be based in Northern Ireland and that supplies from Northern Ireland are not considered as imports. Please refer to Q&As 1700, Q&A 1701, Q&A 1702.

My EU/EEA-based company has registered a substance, which is exported and stored in a warehouse in the UK(Great Britain) and then imported in the EU/EEA. How can we continue this activity after the end of the transition period?

After the end of transition period, trading the substance back to the EU/EEA may be considered as re-import into the EU/EEA.

A re-imported registered substance does not need to be registered again, as long as the conditions for re-import set out in Article 2(7)(c) of REACH are fulfilled. These conditions are outlined in Q&A 1076, and further elaborated in the Guidance on registration section 2.2.3.6.

In Northern Ireland, REACH continues to apply after the transition period. This means, inter alia, that substances shipped from Northern Ireland to the EU/EEA are not considered as imports. Please refer to Q&A 1700 for further details.

Categories Display